Agennix, a company associated with Baylor College of Medicine, Texas, makes a
recombinant form of human lactoferrin for use in wound healing. This is
based on research on human milk and its properties. They are doing clinical
trials. There are a number of patents but human milk component patenting is
off-topic on this list.
Valerie W. McClain
http://www.agennix.com/
"Recombinant human lactoferrin (rhLF) is identical in all material respects
to native lactoferrin. As a result of this new technology, Agennix' lactoferrin
is now in Phase II human clinical trials for the treatment of cancer and
diabetic wounds."
***********************************************
To temporarily stop your subscription: set lactnet nomail
To start it again: set lactnet mail (or digest)
To unsubscribe: unsubscribe lactnet
All commands go to [log in to unmask]
The LACTNET mailing list is powered by L-Soft's renowned
LISTSERV(R) list management software together with L-Soft's LSMTP(R)
mailer for lightning fast mail delivery. For more information, go to:
http://www.lsoft.com/LISTSERV-powered.html